Pegzilarginase

Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia.^[1][2]

Pegzilarginase

Clinical data
Trade names	Loargys
Other names	AEB-1102
Routes of administration	Intravenous
ATC code	A16AB24 (WHO)
Legal status
Legal status	EU: Rx-only[1][2]
Identifiers
CAS Number	1659310-95-8
PubChem SID	405226561
DrugBank	DB14780
UNII	4YV4KW88GD
KEGG	D11695
Chemical and physical data
Formula	C1554H2492N416O463S6
Molar mass	34603.84 g·mol−1

The most common side effects include allergic reactions.^[1]

Pegzilarginase was approved for medical use in the European Union in December 2023.^[2]

Medical uses

Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia.^[1][2]

Society and culture

Legal status

In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia.^[1] The applicant for this medicinal product is Immedica Pharma AB.^[1] Pegzilarginase was approved for medical use in the European Union in December 2023.^[2]

Brand names

Pegzilarginase is the international nonproprietary name.^[3]

Pegzilarginase is sold under the brand name Loargys.^[1]